226 related articles for article (PubMed ID: 18025811)
1. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
2. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on
Gao J; Zhou J; Liu C; Pan Y; Lin X; Zhang Y
J Cancer Res Clin Oncol; 2024 May; 150(5):272. PubMed ID: 38795250
[TBL] [Abstract][Full Text] [Related]
8. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-D-glucose in human pancreatic carcinoma xenografts and in inflammation models.
Hellwig D; Menges M; Schneider G; Moellers MO; Romeike BF; Menger MD; Kirsch CM; Samnick S
Nucl Med Biol; 2005 Feb; 32(2):137-45. PubMed ID: 15721759
[TBL] [Abstract][Full Text] [Related]
9. Head-to-Head Comparison of SSTR Antagonist [
Viswanathan R; Ballal S; Yadav MP; Roesch F; Sheokand P; Satapathy S; Tripathi M; Agarwal S; Moon ES; Bal C
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543061
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results.
Ambrosini V; Zompatori M; De Luca F; Antonia D; Allegri V; Nanni C; Malvi D; Tonveronachi E; Fasano L; Fabbri M; Fanti S
J Nucl Med; 2010 Dec; 51(12):1950-5. PubMed ID: 21078794
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
12. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
13. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
Al-Toubah T; Montilla-Soler J; El-Haddad G; Haider M; Strosberg J
J Nucl Med; 2023 Dec; 64(12):1895-1898. PubMed ID: 37797976
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings.
Naswa N; Sharma P; Soundararajan R; Karunanithi S; Nazar AH; Kumar R; Malhotra A; Bal C
Abdom Imaging; 2013 Jun; 38(3):552-60. PubMed ID: 22743840
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
17. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
[No Abstract] [Full Text] [Related]
18. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours.
Lopci E; Nanni C; Rampin L; Rubello D; Fanti S
Minerva Endocrinol; 2008 Sep; 33(3):277-81. PubMed ID: 18846030
[TBL] [Abstract][Full Text] [Related]
19. Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET.
Henriksen G; Schottelius M; Poethko T; Hauser A; Wolf I; Schwaiger M; Wester HJ
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1653-7. PubMed ID: 15309330
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
Giesel FL; Kratochwil C; Mehndiratta A; Wulfert S; Moltz JH; Zechmann CM; Kauczor HU; Haberkorn U; Ley S
Eur J Radiol; 2012 Oct; 81(10):2820-5. PubMed ID: 22236704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
